文献速递临床试验与 GCP流行病学与生物统计

良性前列腺增生新型手术治疗方式的疗效与安全性比较:系统综述与网状Meta分析

Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network meta-analysis.
PubMed 文献 · BMJ · 2019-11-14

该系统综述与网状Meta分析纳入109项随机对照试验共13676名受试者,比较九种内镜下前列腺手术方式。结果显示,与单极经尿道前列腺电切术相比,八种新术式在控制出血方面更优;在Qmax和IPSS方面,剜除术在术后6、12个月优于切除与汽化术,并维持至24、36个月;剜除术短期暂时性尿失禁可能仍值得关注(OR 1.92,95%CI 1.39至2.65)。

要点

  • 与单极TURP相比,八种新术式控制出血更优,导尿时间更短、术后血红蛋白下降更少、血块潴留更少、输血率更低。
  • 术后12个月Qmax相对单极TURP的平均差:双极剜除2.42 mL/s(95%CI 1.11至3.73)、二极管激光剜除1.86(-0.17至3.88)、钬激光剜除1.07(0.07至2.08)。
  • 与切除术式相比,剜除术短期暂时性尿失禁可能仍值得关注(OR 1.92,95%CI 1.39至2.65)。

核心结论

  • 八种良性前列腺增生新型内镜手术方式与单极TURP相比似乎安全性更优。
  • 在这些新术式中,剜除术的Qmax和IPSS值优于汽化术和切除术。

研究设计与样本

  • 系统综述与随机对照试验网状Meta分析,检索PubMed、Embase和Cochrane数据库自建库至2019年3月31日。
  • 纳入比较单极、双极或各种激光系统(钬激光、铥激光、磷酸钛氧钾激光或二极管激光)行前列腺汽化、切除或剜除治疗良性前列腺增生的随机对照试验。
  • 共纳入109项试验、13676名受试者,评估九种手术方式,采用频率学方法进行网状Meta分析并计算各治疗排名概率。
  • 主要结局为术后12个月最大尿流率(Qmax)和国际前列腺症状评分(IPSS);次要结局为术后6、24、36个月Qmax和IPSS、围手术期参数及手术并发症。

主要发现

  • 术后6和12个月剜除术的Qmax和IPSS值优于切除和汽化方法,差异维持至术后24和36个月。
  • 术后12个月Qmax相对单极TURP平均差最好的三种方法为双极剜除2.42 mL/s(95%CI 1.11至3.73)、二极管激光剜除1.86(-0.17至3.88)、钬激光剜除1.07(0.07至2.08);表现最差为二极管激光汽化-1.90(-5.07至1.27)。
  • 术后12个月IPSS相对单极TURP平均差最好的三种方法为二极管激光剜除-1.00(-2.41至0.40)、双极剜除0.87(-1.80至0.07)、钬激光剜除-0.84(-1.51至0.58);表现最差为二极管激光汽化1.30(-1.16至3.76)。
  • 八种新方法较单极TURP控制出血更好,导尿时间更短、术后血红蛋白下降更少、血块潴留事件更少、输血率更低。
  • 与切除方法相比,剜除方法短期暂时性尿失禁可能仍值得关注(OR 1.92,95%CI 1.39至2.65)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy and safety of different endoscopic surgical treatments for benign prostatic hyperplasia. DESIGN: Systematic review and network meta-analysis of randomised controlled trials. DATA SOURCES: A comprehensive search of PubMed, Embase, and Cochrane databases from inception to 31 March 2019. STUDY SELECTION: Randomised controlled trials comparing vapourisation, resection, and enucleation of the prostate using monopolar, bipolar, or various laser systems (holmium, thulium, potassium titanyl phosphate, or diode) as surgical treatments for benign prostatic hyperplasia. The primary outcomes were the maximal flow rate (Qmax) and international prostate symptoms score (IPSS) at 12 months after surgical treatment. Secondary outcomes were Qmax and IPSS values at 6, 24, and 36 months after surgical treatment; perioperative parameters; and surgical complications. DATA EXTRACTION AND SYNTHESIS: Two independent reviewers extracted the study data and performed quality assessments using the Cochrane Risk of Bias Tool. The effect sizes were summarised using weighted mean differences for continuous outcomes and odds ratios for binary outcomes. Frequentist approach to the network meta-analysis was used to estimate comparative effects and safety. Ranking probabilities of each treatment were also calculated. RESULTS: 109 trials with a total of 13 676 participants were identified. Nine surgical treatments were evaluated. Enucleation achieved better Qmax and IPSS values than resection and vapourisation methods at six and 12 months after surgical treatment, and the difference maintained up to 24 and 36 months after surgical treatment. For Qmax at 12 months after surgical treatment, the best three methods compared with monopolar transurethral resection of the prostate (TURP) were bipolar enucleation (mean difference 2.42 mL/s (95% confidence interval 1.11 to 3.73)), diode laser enucleation (1.86 (-0.17 to 3.88)), and holmium laser enucleation (1.07 (0.07 to 2.08)). The worst performing method was diode laser vapourisation (-1.90 (-5.07 to 1.27)). The results of IPSS at 12 months after treatment were similar to Qmax at 12 months after treatment. The best three methods, versus monopolar TURP, were diode laser enucleation (mean difference -1.00 (-2.41 to 0.40)), bipolar enucleation (0.87 (-1.80 to 0.07)), and holmium laser enucleation (-0.84 (-1.51 to 0.58)). The worst performing method was diode laser vapourisation (1.30 (-1.16 to 3.76)). Eight new methods were better at controlling bleeding than monopolar TURP, resulting in a shorter catheterisation duration, reduced postoperative haemoglobin declination, fewer clot retention events, and lower blood transfusion rate. However, short term transient urinary incontinence might still be a concern for enucleation methods, compared with resection methods (odds ratio 1.92, 1.39 to 2.65). No substantial inconsistency between direct and indirect evidence was detected in primary or secondary outcomes. CONCLUSION: Eight new endoscopic surgical methods for benign prostatic hyperplasia appeared to be superior in safety compared with monopolar TURP. Among these new treatments, enucleation methods showed better Qmax and IPSS values than vapourisation and resection methods. STUDY REGISTRATION: CRD42018099583.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Huang SW, Tsai CY, Tseng CS, et al. Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network meta-analysis. BMJ. 2019. PMID: 31727627. doi:10.1136/bmj.l5919

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。